Medication info
Centos Tablet (Terbinafine Hydrochloride)

Centos Tablet (Terbinafine Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Terbinafine Hydrochloride›140.625mg / 1 tablet
Manufacturer / importer
Medica Korea Co., Ltd.
Appearance
White to off-white round tablet
Packaging
30 tablets/bottle, 100 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 200401370 · Notified 2004.11.25 · Insurance code 646001470

Summary

Main use
Treatment of onychomycosis and skin fungal infections (such as tinea pedis and tinea corporis), and tinea capitis
Who takes it
Adults · Children
Adult dose
Administer terbinafine 125 mg per dose 2 times daily or 250 mg per dose once daily. The duration of administration according to the condition is as follows. 1) Dermatophytosis Tinea pedis (interdigital, plantar/moccasin type): 2~6 weeks Tinea corporis: 2∼4 weeks Tinea cruris: 2~4 weeks 2) Onychomycosis Usually administer for 6 weeks~3 months. In cases of infection of the fingernails or relatively small toenails, or in younger patients, the treatment period may be shortened to 3 months or less. A treatment period of 3 months is usually sufficient for toenail infections, but some patients may require 6 months or longer. The treatment period may be longer in patients with slow nail growth. For patients with a creatinine clearance of less than 50 mL per minute, reduce the daily dose by 1/2.
Child dose
Administer to children aged 2 years and older. Administration is not recommended for children younger than 2 years because there is no experience with its use in this age group. Tinea capitis: 4 weeks 1) Body weight less than 20 kg (under 5 years): Administer 62.5 mg per dose once daily. Because experience with administration is limited, the decision to administer should be based on consideration of the benefits and risks of treatment. 2) Body weight 20~40 kg (5~12 years): Administer 125 mg per dose once daily. 3) Body weight over 40 kg (over 12 years): Administer 250 mg per dose once daily.

Ingredients

Manufacturer
Medica Korea Co., Ltd.

Efficacy & effects

Treatment of onychomycosis and skin fungal infections (such as tinea pedis and tinea corporis), and tinea capitis

  • Dermatomycosis
  • athlete's foot
  • tinea corporis
  • tinea cruris
  • onychomycosis
  • tinea capitis
View approved original text

This medication is used to treat athlete's foot, tinea corporis, tinea cruris, and onychomycosis caused by Dermatophytes in adults. It is also effective in treating tinea capitis in children.

How to take

Adult dose

Administer terbinafine 125 mg per dose 2 times daily or 250 mg per dose once daily. The duration of administration according to the condition is as follows. 1) Dermatophytosis Tinea pedis (interdigital, plantar/moccasin type): 2~6 weeks Tinea corporis: 2∼4 weeks Tinea cruris: 2~4 weeks 2) Onychomycosis Usually administer for 6 weeks~3 months. In cases of infection of the fingernails or relatively small toenails, or in younger patients, the treatment period may be shortened to 3 months or less. A treatment period of 3 months is usually sufficient for toenail infections, but some patients may require 6 months or longer. The treatment period may be longer in patients with slow nail growth. For patients with a creatinine clearance of less than 50 mL per minute, reduce the daily dose by 1/2.

Child dose

Administer to children aged 2 years and older. Administration is not recommended for children younger than 2 years because there is no experience with its use in this age group. Tinea capitis: 4 weeks 1) Body weight less than 20 kg (under 5 years): Administer 62.5 mg per dose once daily. Because experience with administration is limited, the decision to administer should be based on consideration of the benefits and risks of treatment. 2) Body weight 20~40 kg (5~12 years): Administer 125 mg per dose once daily. 3) Body weight over 40 kg (over 12 years): Administer 250 mg per dose once daily.

Precautions

This medication should ideally not be used in patients with chronic liver disease or active liver disease. Before taking this medication, a liver function test must be performed to check for any liver function issues. Regular liver function tests should continue to be conducted 4 to 6 weeks after starting treatment to monitor liver health. If liver function test results increase, this medication should be stopped immediately, and if symptoms of liver dysfunction (nausea, loss of appetite, fatigue, vomiting, upper right abdominal pain, jaundice, dark urine, diarrhea) occur, consult a physician immediately. This medication can rarely cause liver failure, so if liver damage is suspected, use should be stopped immediately and specialized medical attention sought. Individuals with an allergy to this medication or its components should not take it. This medication is contraindicated in patients with hematological diseases (neutropenia, pancytopenia, agranulocytosis, thrombocytopenia), severe renal impairment, nursing mothers, and infants under 2 years old. Patients with genetic lactose intolerance or specific enzyme deficiencies should not take this medication. Caution should be exercised when prescribing this medication to patients with renal impairment, elderly individuals aged 65 or older, or children weighing less than 20 kg. This medication can rarely cause serious skin reactions, so discontinue use and visit a hospital if any abnormal skin symptoms arise. Patients with autoimmune diseases such as psoriasis or systemic lupus erythematosus require special caution when using this medication. This medication is metabolized in the liver, so side effects may be more severe in those with hepatic dysfunction. During treatment with this medication, symptoms such as myalgia, arthralgia, dizziness, headache, dyspepsia, nausea, rash, itching, and others may appear; if symptoms are severe, consult a physician. This medication may interact with other drugs, especially when taken concurrently with other drugs metabolized in the liver, requiring dose adjustment or caution. Women who are pregnant or may become pregnant should consult a physician before taking this medication, and nursing mothers should discontinue breastfeeding while taking this medication. Experience with this medication in young children is limited, so the decision to use it should be made cautiously. Elderly individuals may experience increased drug concentrations due to reduced liver and kidney function, so their condition should be closely observed during use. Overdose may result in headache, nausea, abdominal pain, and dizziness, requiring immediate medical treatment. This medication should be kept out of reach of children, stored in a sealed container to prevent exposure to air or moisture, and kept at room temperature between 1°C and 30°C away from direct sunlight.

Side effects

Hepatic and biliary dysfunction, hepatitis, cholestasis, jaundice, rash, skin itching, fever, nausea, vomiting, loss of appetite, fatigue, elevated γ-GTP, elevated AST/ALT, elevated LDH, elevated ALP, neutropenia, pancytopenia, agranulocytosis, thrombocytopenia, pharyngitis, fever, lymphadenopathy, purpura, petechiae, leukopenia, anemia, rash, itching, photosensitivity reactions, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, erythema multiforme, toxic skin rash, exfoliative dermatitis, vesicular dermatitis, psoriatic rash, worsening of psoriasis, hair loss, musculoskeletal reactions, arthralgia, myalgia, weakness, elevated CPK, rhabdomyolysis, hypotension, dyspnea, chest tightness, urticaria, erythema, facial edema, lymphangiectasia, abdominal distension, decreased appetite, indigestion, mild abdominal pain, diarrhea, discomfort in the epigastric region, thirst, vomiting, glossitis, depression, anxiety, headache, loss of taste, taste disorders, dizziness, drowsiness, sensory disturbances, decreased sensation, decreased attention, insomnia, elevated BUN, frequent urination, visual disturbances, tinnitus, anaphylactic reaction, angioedema, systemic lupus erythematosus, elevated total cholesterol, elevated triglycerides, fatigue, tongue discoloration, palpitations, edema, menstrual irregularities, paralysis, systemic disorders, fever, fatigue, weight loss, anaphylactic reaction, serum sickness-like reaction, blurred vision, decreased vision, hearing impairment, auditory dysfunction, vasculitis, permanent anosmia, anosmia, hyposmia, eosinophilia, drug rash, pancreatitis, rhabdomyolysis, influenza-like illness, elevated blood creatine phosphokinase, headache, nausea, upper abdominal pain, dizziness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air or moisture from entering. It is preferable to store it at room temperature between 1°C and 30°C, avoiding extremely cold or hot places.

Appearance and packaging

Appearance

White to off-white round tablet

Package unit

30 tablets/bottle, 100 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.